Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$17.41 - $19.89 $7.17 Million - $8.19 Million
-411,727 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $899,393 - $1.19 Million
-62,328 Reduced 13.15%
411,727 $7.35 Million
Q1 2020

May 15, 2020

SELL
$11.67 - $22.53 $712,231 - $1.38 Million
-61,031 Reduced 11.41%
474,055 $7.69 Million
Q4 2019

Feb 14, 2020

SELL
$16.33 - $21.37 $2.53 Million - $3.31 Million
-154,739 Reduced 22.43%
535,086 $9.63 Million
Q3 2019

Nov 14, 2019

SELL
$16.3 - $23.37 $12.5 Million - $18 Million
-768,160 Reduced 52.69%
689,825 $14 Million
Q2 2019

Aug 14, 2019

BUY
$13.1 - $22.1 $6.69 Million - $11.3 Million
510,924 Added 53.95%
1,457,985 $32.2 Million
Q1 2019

May 15, 2019

BUY
$8.38 - $15.5 $7.94 Million - $14.7 Million
947,061 New
947,061 $12.9 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $91.7M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.